Swing Trade Ideas

🏃🚀✅  VTAK 35%, high 1.62 

🏃🚀✅ IKT  UP 65%, high 2.65 premarket  🚀 

🏃🚀✅ VTAK UP 46%  🚀 

🏃🚀✅ IMUX 86%  🚀 

🏃🚀✅ HUMA high 1.28, up 42%  🚀 

 ✅ SNGX potential entry: $1.05 – $1.15

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.60
🎯 PT3: $2.70 – $3.80

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently received positive orphan drug opinion for SGX945 in Behcet's disease, upcoming catalyst:  ongoing enrollment in phase 3 trial for HyBryte, company specializing in the development and commercialization of therapies for rare and underserved diseases,  Zacks Small-cap price target $35, Alliance Global Partners price target $6, 

✅ FOFO entry: $2.90 – $2.95

🎯 PT1: $3.30 – $3.90
🎯 PT2: $4.00 – $4.60
🎯 PT3: $4.70 – $5.50

🚫 Stop: Below $2.75 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to near 52 wk low from recent IPO high above 65, a consulting and asset management firm 

  ✅ HCAT potential entry: $1.70
🎯 PT1: $2.10 – $2.80
🎯 PT2: $2.90 – $3.70
🎯 PT3: $3.80 – $4.50
🚫 Stop: Below $1.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support near 52wk low, company focuses on healthcare data analytics and technology, providing cloud based data operating system and analytic tools to hospitals and health systems, Citigroup price target $2.75, Stifel price target $3.75 

 ✅ GTBP potential entry: $0.45
🎯 PT1: $0.70 – $1.20
🎯 PT2: $1.30 – $1.80
🎯 PT3: $1.90 – $2.50
🚫 Stop: Below $0.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
recently received FDA clearance for IND, previously announced advancing phase 1 trial of GTB-3650 for relapsed blood cancers, update data expecting Q1 2026, other upcoming catalysts: 1)company develops cancer therapies using proprietary TriKE platform, designed to activate natural killer cells to attack cancer cells, ROTH MKM price target $8, does have mixed shelf, be mindful on next spike, have until May 16, 2026 to regain compliance, 

 ✅ SATL entry: $3.10 – $3.20
🎯 PT1: $3.50 – $3.90
🎯 PT2: $4.00 – $4.60
🎯 PT3: $4.70 – $5.50
🚫 Stop: Below $2.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high above 5.50, company is a satellite imaging company, providing services to military, government, defense, agriculture, oil & mining, and AI monitoring, upcoming catalysts: 1) Cantor Global Tech & Industrial Growth conference in New York on March 10-11, recently announced launching of Aleph Observer, Cantor Fitzgerald buy rating target price $7, Northland initiated outperform, recently extended existing agreement with the Government of Albania, recent offering price at $4.73 per share 

: ✅ ENLV entry: 1.05 – 1.10
🎯 PT1: 1.40 – 1.80
🎯 PT2: 1.90 – 2.60
🎯 PT3: 2.70 – 3.80
🚫 Stop: Below 0.90 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently closed $212M private placement, expanding digital asset strategy, adopts RAIN token treasury strategy and advances Allocetra knee osteoarthritis program, recently announced positive 6-month topline data, demonstrating durable and persistent pain reduction and improved function in primary age-rated patients with mod to severe knee osteoarthritis, company focuses on immunotherapy, main program is Allocetra, an off the shelf macrophage-reprogramming therapy intended to restore macrophages to healthy state, treating inflammatory and degenerative disease,  HC Wainwright raised price to $13 from $7 

  ✅ AUID entry: $1.25 – $1.35
🎯 PT1: $1.60 – $1.90
🎯 PT2: $2.00 – $2.40
🎯 PT3: $2.50 – $3.20
🚫 Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high, company focuses on biometric identity authentication, recently selected to support retail deployments of kiosks in U.S, recently announced integration with ServiceNow to deliver secure, frictionless identity verification and authentication for contact centers 

 ✅ LRHC entry: $1.05 – $1.15
🎯 PT1: $1.40 – $1.90
🎯 PT2: $2.00 – $2.50
🎯 PT3: $2.60 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to key support near 52wk low from recent high, company is a real estate brokerage and PropTech holding company, recently expanded int AI infrastructure and data centers, recent 1/10 reverse split, ultra small float, recently signed contract to acquire Central Florida Site for AI data center, 

   ✅ CIGL potential entry: $1.55 – $1.65
🎯 Potential PT1: $2.00 – $2.50
🎯 PT2: $2.60 – $3.30
🎯 PT3: $3.40 – $3.90
🚫 Potential Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to near 52wk low from recent high, recently entered merger agreement with YOOV Group HOlding in a $600 M deal, previously acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients 

 ✅ CRDL entry: .90 – 1.00
🎯 PT1: 1.30 – 1.80
🎯 PT2: 1.90 – 2.60
🎯 PT3: 2.70 – 3.50
🚫 Stop: Below 0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
near 52wk low , recently announced positive phase II ARCHER Trial data for CardioIRx, recently secured USA patent for hear drugs, company focuses on novel anti-inflammatory and anti-fibrotic therapies for heart disease, its lead drug, CardioIRx (an oral cannabidiol formulation) is designed to treat serious cardiac conditions like acute myocarditis and recurrent pericarditis by modulating inflammatory pathways involved in fibrosis and heart damage.  First Berlin Equity Research price target $7.80, Canaccord Genuity buy rating, HC Wainwright price target $9, does have mixed shelf 

 ✅ NVVE potential entry: $1.10 – $1.15
🎯 PT1: $1.30 – $1.70
🎯 PT2: $1.80 – $2.30
🎯 PT3: $2.40 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to key support from recent high above 5, company focuses on EV charging and vehicle-to-gid (V2G), recently secured $5M contract for three battery energy storage systems in Denmark, does have mixed shelf, be mindful on next spike 

 ✅ VIVS potential entry: $2.0
🎯 PT1: $2.20 – $2.70
🎯 PT2: $2.80 – $3.50
🎯 PT3: $3.60 – $4.30
🚫 Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to key support form recent high above $3,  previously signed distribution agreements with JCBio in Korea and Tekon Biotech in China for NAMKind Toxicology Services, company focuses on biotech services including testing drugs using 3D human liver and intestine tissue models and AI-driven toxicology platforms. upcoming catalyst: 1) new data announcement on NAMKind Intestine models demonstrating a high correlation in liver  toxicity  and intestinal side effects including diarrhea at the upcoming Society of Toxicology meeting in San Diego March 22-25 

 ✅ KULR potential entry: $2.70 – $2.80
🎯 Potential PT1: $3.20 – $3.80
🎯 PT2: $3.90 – $4.50
🎯 PT3: $4.60 – $5.80
🚫 Potential Stop: Below $2.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently awarded five-year preferred battery supply agreement, previously entered join development collaboration for battery backup unit for $100M, joined Open compute project as platinum member, company develops and commercializes thermal management technologies focused on battery safety, heat dissipation and energy/system solutions 

 ✅ GNSS entry: $1.95 – $2.00
🎯 PT1: $2.30 – $2.80
🎯 PT2: $2.90 – $3.50
🎯 PT3: $3.60 – $3.90
🚫 Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently received $2M order from Singapore Navy for LRAD 950nxtS, previously announced $1M follow-on order from nuclear energy operator, also recently entered strategic partnership with Julie Parker Communications, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating 

 ✅ SNDL potential entry: $1.40 – $1.50

🎯 Potential PT1: $1.70 – $2.50
🎯 PT2: $2.60 – $3.50
🎯 PT3: $3.60 – $4.40

🚫 Potential Stop: Below $1.15 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 MJ related ticker, recently amended agreement to acquire Cannabis Retail stores,  company produces, distributes, and sells cannabis products, analyst rating price target $5 

 ✅ MVST potential entry: $2.20 – $2.30
🎯 Potential PT1: $2.60 – $3.60
🎯 PT2: $3.70 – $4.30
🎯 PT3: $4.40 – $5.00
🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high above 7, recently raised 2025 gross market outlook to 35% while advancing all-solid-state battery and European partnership , company designs, develops and manufactures advanced lithium-ion battery technologies from core cell materials to full battery packs and energy-store systems, their batteries are used for electric commercial vehicles (buses, trucks, specialty vehicles), heavy duty transportation, and utility-scare energy storage systems, analysts strong buy rating, target price $6, 

  ✅ UAVS entry: $0.90 – $1.00

🎯 PT1: $1.20 – $1.50
🎯 PT2: $1.60 – $2.20
🎯 PT3: $2.30 – $3.20

🚫 Stop Loss: Below $0.80 or 2%–5% (or daily max risk per trade)

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent highi, recently announced strategic procurement in Malaysia, announced expanded into Canada with eBee VISION deployment, recently delivered First eBee X manufacturing kits to Vyom drones, marking milestone toward local production in India, previously sold eBee VISION Drones to U.S Army in Germany, partnered wit Makville to bring drones to Egypt, company designs and delivers unmanned aerial system including drones, sensors, software and data analytics solutions globally for commercial, government, agricultural, energy, infrastructure, and defense applications, does have mixed shelf, be mindful on next spike 

✅ HOTH entry: $0.90 – $1.00

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.00

🚫 Stop Loss: Below $0.80 or 2%–5% (or daily max risk per trade)

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 previously accepted into $NVDA Connect Program to accelerate AI-driven drug development, previously partnered and expanded its AI Initiative through $NVDA AI enterprise subscription license, previously entered joint venture with $SILO Pharma to commercialize VA-invented obesity Drug, expanded phase II clinical trial for HT-001, topical gel treating skin toxicities, across Europe in collaboration with ICON, recent data demonstrated significant reduction in tumor growth, announced patent to develop anti-obesity treatments with US Depart. Of Veterans Affairs, also previously purchased up to $1M of $BTC.X as treasury reverse asset, upcoming catalysts: 1) IND filing for HT-KIT, which recently announced positive data, suppressing tumor growth in preclinical models, expected to submit early 2026, Austria D. Boral capital price target $5, HC Wainwright price target $4 

 ✅ MAIA Potential Entry: $1.90 – $1.95
🎯 PT1: $2.30 – $2.50
🎯 PT2: $2.60 – $3.30
🎯 PT3: $3.40 – $3.80
🚫 Stop Loss: Below $1.80 or 2%–5% (or daily max risk per trade)
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Another rinse and repeat,  back to support from recent high, recently secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target $14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago, upcoming catalysts: 1) update clinical data on efficacy/safety for phase 2 

 ✅ JXG Entry: $4.00
🎯 PT1: $4.40 – $4.80
🎯 PT2: $4.90 – $5.60
🎯 PT3: $5.70 – $6.80
🚫 Stop Loss: Below $3.80 or 2%–5% (or daily max risk per trade)
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back to support from recent high above 8, company focuses on consumer services, primarily related to tourism, travel services 

✅ VTAK Potential Entry: $1.15 – $1.20

🎯 PT1: $1.50 – $2.30
🎯 PT2: $2.40 – $2.80
🎯 PT3: $2.90 – $3.50

🚫 Stop Loss: Below $1.10 or 2%–5% (or daily max risk per trade)

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to near 52wk low from recent high, small float, recently received new VIVO purchase order from hospital in Slovenia, Previously entered distribution agreement with FuMedica, and announced two patents to be issued by USPTO, previously received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery, 

 ✅ FATE Entry: $1.10 – $1.15

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.30

🚫 Stop Loss: Below $1.00 or 2%–5% (or daily max risk per trade)

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high, company focuses on developing cellular immunotherapies for cancer and autoimmune diseases, Wedbush buy rating, 

✅ CGTX potential entry: $1.05

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.70
🎯 PT3: $2.80 – $3.50

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high above 2.50, clinical stage biopharmaceutical company focuses on age-related neurodegenerative diseases specifically Alzheimer's and dementia with Lew bodies, lead candidate is zervimesine (CT1812), oral formulation designed to penetrate the blood-brain barrier and target pathways implicated in neurodegeneration,  HC Wainwright price target $3,  B. Riley Securities raised price target to $3, does have mixed shelf, be mindful on next spike 

 ✅ XPON entry: $0.70 – $0.80

🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.50

🚫 Stop: Below $0.60 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 back to support from recent high above 1, company designs, assembles, manufactures, and sells lithium iron phosphate batteries and related accessories in North America, recently announced upcoming release of three lithium battery models, announced batter models available in second half of 2026, company have until 7/28/2026 to bring price above $1 in order to regain nasdaq compliance, does have an additional 180-day extension, does have mixed shelf, be mindful on next spike, 

✅ $MRKR Potential Entry: $1.40 – $1.50
🎯 Potential PT1: $1.80 – $2.50
🎯 PT2: $2.60 – $2.70
🎯 PT3: $2.80 – $3.40

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: Medium | Catalyst-Driven | Technical Setup

back to support from recent high,recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell  therapies for hematological malignancies and solid tumors,  HC Wainwright price target  $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8, Brookline buy rating,

✅ $IKT Entry: $1.50 – $1.60
🎯 PT1: $1.90 – $2.40
🎯 PT2: $2.50 – $2.80
🎯 PT3: $2.90 – $3.40

🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 company focuses on developing therapies for neurodegenerative disorders, especially Parkinson's disease and related conditions, upcoming catalyst: phase 3 study for Pulmonary arterial hypertension expected to begin Q1 2026, HC Wainwright price target $8, Cantor Fitzgeral price target $4,  does have active mixed shelf, be mindful on next spike 

 ✅ $BMEA Entry: $1.10 – $1.20
🎯 PT1: $1.50 – $2.80
🎯 PT2: $2.90 – $3.60
🎯 PT3: $3.70 – $4.50

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high, company focuses on oral small molecule therapies for metabolic disease, such as type to diabetes and obesity, lead candidate icovamenib, targets a key protein involved in gene regulation, aiming to improve glycemic control and metabolic outcomes, upcoming catalyst: 1) Q1 2026 to enroll first participant in COVALENT -211 phase IIb trial and provide business update, Director and Officer Rainer Erdtmann recently acquired shares, Interim CEO & director recently bought 667% more shares, Rodman & Renshaw buy rating, D. Boral Capital price target $12.00, HC Wainwright buy rating 

✅ $AMC Entry: $1.30 – $1.35
🎯 PT1: $1.70 – $2.20
🎯 PT2: $2.30 – $2.80
🎯 PT3: $2.90 – $3.50

🚫 Stop: Below $1.30, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 AMC potential swing 1.40/.45, stop if below 1.30 or daily max risk per trade @ near 52wk low,  Macquarie price target $2 

 ✅ $HUMA Entry: $0.90

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.60

🚫 Stop: Below $0.85, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high, company develops off-the=shelf, implantable bioengineered huma tissues designed to improve treatment of vascular and organ damage, plan to file MAA with Israel Ministry of Health for approval of Acellular Tissue engineered vessel for Arterial Trauma Repair, Benchmark price target $10, D. Boral capital price target $25, does have mixed shelf, be mindful on next spike 

✅ $SIDU Entry: $2.20 – $2.30

🎯 PT1: $2.60 – $3.30
🎯 PT2: $3.40 – $3.80
🎯 PT3: $3.90 – $4.40

🚫 Stop: Below $2.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 back to near support from recent high above 5.50, recently launched into High-Margin Satellite data services market, previously won subcontractor role on NASA radar design study, also advanced orbital debris tracking with LIzzieSat Radar Integration, completed its NASA phase II sequential award with Xiomas Technologies, recently unveiled Edge computing breakthrough for real0time fire detection, previously awarded FIVE-YEAR $21 M contract under the Tobyhanna Army Depot (TYAD) industrial multiple award task order contract (MATOC) program for fabrication and on-call services for critical components used in TYAD'S operation, does have mixed shelf, be mindful on next spike 

 ✅ $OVID Entry: $1.35 – $1.45
🎯 PT1: $1.70 – $2.40
🎯 PT2: $2.50 – $3.30
🎯 PT3: $3.40 – $3.80
🚫 Stop: Below $1.10, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

company focuses on developing treatment for neurological diseases, back to support from recent high, recently unveils pipeline advanced targeting drug-resistance epilepsy and neuropsychiatric disorders, LifeSci Capital price target $4, HW Wainwright price target $2, Roth Capital price target $3,

 ✅ $ACRV Entry: $1.50 – $1.60
🎯 PT1: $1.80 – $2.50
🎯 PT2: $2.60 – $3.80
🎯 PT3: $3.90 – $4.40
🚫 Stop: Below $1.40, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 use a proprietary proteomics/phosphoproteomics platform (AP3) to match tumor's signaling pathways to drug mechanisms, CFO Adam Levy recently purchased shares, COO Eric Devroe also purchased shares, Citizens JMP buy rating, Oppenheimer price target $8, Piper Sandler price target $8 

 ✅ NNOX Entry: $2.4
🎯 PT1: $2.80 – $3.40, 🎯 PT2: $3.50 – $3.80, 🎯 PT3: $3.90 – $4.70
🚫 Stop: Below $2.45 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst Driven | Technical Setup 

 back to near 52wk low, recently announced securing  FDA 510 (K) clearance for TAP2D Image enhancement on Nanox ARC systems, recent new collaboration announcement with Adriamed d.o.o Beograd,  company develops medical imaging systems, D. Boral price target $8, 

 ✅ HCAT
🎯 Entry: $2.10 – $2.15, 🎯 PT1: $2.40 – $2.80, 🎯 PT2: $2.90 – $3.70, 🎯 PT3: $3.80 – $4.50
🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst Driven | Technical Setup 

 back to support  near 52wk low,  company focuses on healthcare data analytics and technology, providing cloud based data operating system and analytic tools to hospitals and health systems,  Citigroup price target $2.75, Stifel price target $3.75 

 ✅ $ONCY Entry: $0.90 – $0.95
🎯 PT1: $1.20 – $1.80,🎯 PT2: $1.90 – $2.5,🎯 PT3: $2.60 – $3.80

🚫 Stop: Below $0.80, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high, company focuses on the development of first in class intravenously delivered oncolytic virus designed to selectively destroy cancer cells and stimulate the immune system against tumors, previously announced promising Pelareorep data in colorectal cancer, FDA recently agreed on phase 3 trial design for elareorep in pancreatic cancer, planning to launch immunotherapy trial in pancreatic cancer in 2026,  Lake Street buy rating,  RBC Capital buy rating, HC Wainwright raised target price to $10 from $5 

✅ $CRON Entry: $2.35 – $2.45
🎯 PT1: $2.70 – $3.40, 🎯 PT2: $3.50 – $4.30, 🎯 PT3: $4.40 – $5.50

🚫 Stop: Below $2.00, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 MJ ticker, focuses on cultivation, production, distribution for medical and adult use markets 

 ✅ $IMUX Entry: $0.60 – $0.65
🎯 PT1: $0.80 – $1.30, 🎯 PT2: $1.40 – $2.40, 🎯 PT3: $2.50 – $3.40

🚫 Stop: Below $0.50, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 company focuses on developing therapies for chronic inflammatory and autoimmune diseases targeting conditions including: multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other immune-related disorders., upcoming catalysts: 1) top line data from twin phase 3 expected end of 2026,  Chardan Capital buy rating, HC Wainwright price target $8, D. Boral Capital price target $8, company have until June 22, 2026 to bring price up above $1 for 10 consecutive days in order to regain nasdaq compliance. 

✅ $NRSN Entry: $0.80 – $0.90
🎯 PT1: $1.30 – $1.9, 🎯 PT2: $2.00 – $2.7, 🎯 PT3: $2.80 – $3.50

🚫 Stop: Below $0.70, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to near 52wk low, recently announced positive trial results for Alzheimer's drug candidate, D. Boral Capital price target $14, Noble financial buy rating, Alliance Global Partners buy rating,  its leading drug candidate, PrimeC, a combination of ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS) has shown positive clinical data in phase 2b, currently being prepared for commercial-scale production, upcoming catalyst: 1) topline data, phase 3, 2nd of half 2025, 2) full lNDS submission later of 2025, 3) phase 2 alzheimer's trial top line expected 2026, company focuses on neurodegenerative diseases, primarily ALS, with additional pipeline programs targeting Alzheimer's and Parkinson's, does have mixed shelf, be mindful on next spike 

 ✅ $PRSO Entry: $1.00

🎯 PT1: $1.20 – $1.70, 🎯 PT2: $1.80 – $2.50, 🎯 PT3: $2.60 – $3.20

🚫 Stop: Below $0.80, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently announced collaboration with Virewirx, previously secured $1.1M through inducement offer agreement, ,secured $0.9M order from FWA equipment supplier, partnered with WeLink to expand access to high-speed broadband across dense US metro areas, company focuses on fabless semiconductor/mmWave wireless technology, , Benchmark Co buy rating, price target $3, 

✅ $CIGL Entry: $2.00 – $2.05

🎯 PT1: $2.20 – $2.80, 🎯 PT2: $2.90 – $3.30, 🎯 PT3: $3.40 – $3.90

🚫 Stop: Below $1.90, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 recently acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients 

 ✅ $THH entry: $0.60

🎯 PT1: $0.80 – $1.40, 🎯 PT2: $1.50 – $1.80, 🎯 PT3: $1.90 – $3.20

🚫 Stop: Below $0.55, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, does have mixed shelf, be mindful on next spike, 

✅ GTBP Entry: $0.70

🎯 PT1: $1.30 – $1.80, 🎯 PT2: $2.00 – $2.6, 🎯 PT3: $2.70 – $3.30

🚫 Stop: Below $0.60, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently announced advancing phase 1 trial of GTB-3650 for relapsed blood cancers, update data expecting Q1 2026, other upcoming catalysts: 1) submission for GTB-5550 trial expected January 2026, have until May 16, 2026 to regain compliance, company develops cancer therapies using proprietary TriKE platform, designed to activate natural killer cells to attack cancer cells,  ROTH MKM price target $8, does have mixed shelf, be mindful on next spike, keep current support .60 as bottom stop loss 

 ✅  CGC Entry: $1.10 – $1.20

🎯 PT1: $1.50 – $1.90, 🎯 PT2: $2.00 – $2.7,🎯 PT3: $2.80 – $3.70

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, does have mixed shelf, be mindful on next spike, 

 ✅ $OPAD potential entry: $1.25 – $1.35
🎯 PT1: $1.60– $1.80🎯 PT2: $1.90 – $2.40🎯 PT3: $2.50 – $3.50
🚫 Stop: Below $1 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back to support from recent high, offering at $1.80, previously secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China , Alliance global partners price target 3.50

 ✅  CGC Entry: $1.10 – $1.20

🎯 PT1: $1.50 – $1.90, 🎯 PT2: $2.00 – $2.7,🎯 PT3: $2.80 – $3.70

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, does have mixed shelf, be mindful on next spike, 

✅ CYN Entry: $2.35 – $2.45

🎯 PT1: $2.80 – $3.3, 🎯 PT2: $3.40 – $3.8,🎯 PT3: $3.90 – $4.50

🚫 Stop: Below $2.25, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

back to near 52wk low from recent high,  recently expanded dealer network with Candler Automation for DriveMod Tugger in agriculture, announced to deliver additional autonomous vehicles to G&J Pepsi , company focuses on industrial automation, mainly self-driving software and solutions for material handling, warehousing, and industrial fleets, its core products include the Enterprise Autonomy Suite, DriveMod modular autonomous tech and fleet management tools, does have mixed shelf, be mindful on next spike